We’re excited to announce our $200M Series D fundraise led by Double Point Ventures, with @khoslaventures, ARCH Ventures, Bezos Expeditions, NRF, NTI, METIS, @protocollabs @K5Global and others. 🧠🧠

Read the release:

businesswire.com/news/home/2025…

Mount Sinai Neurosurgery is once again at the forefront of #BCI tech & research! We're now enrolling participants for the #INTENT #ClinicalTrial, evaluating @synchroninc's investigational endovascular BCI device for people living with #ALS. @MajidiShahram @IcahnMountSinai

Excited to share we made the @FastCompany Most Innovative Companies 2026 list in the Data Science category. 🔥🔥🔥

View the list: fastcompany.com/most-innovativ…

#FCMostInnovative #BCI

Synchron bags $200M to advance thought-control tech @synchroninc #neurology #paralysis #Funding firstwordhealthtech.com/story/6517684

Neuralink rival company @synchroninc just raised $200 million.

Their CEO @tomoxl joined TITV to explain his plans.

Watch the full episode: thein.fo/47KvWjM

Neuralink rival Synchron raises $200M for brain implant crainsnewyork.com/health-pulse/s…

Company targets pivotal trials of brain-computer interface platform that allows control of digital devices using thought alone.

longevity.technology/news/synchron-…

#neurotech #longevity #investment #BCI #technology

Neuralink rival Synchron raises $200M for brain implant. modernhealthcare.com/health-tech/mh…

We’re excited to announce our $200M Series D fundraise led by Double Point Ventures, with @khoslaventures, ARCH Ventures, Bezos Expeditions, NRF, NTI, METIS, @protocollabs @K5Global and others. 🧠🧠

Read the release:

businesswire.com/news/home/2025…

Our CEO @tomoxl will be on @theinformation TITV today at 8 am PT/11 am ET. Check the stream!

Synchron raised $200 million to advance its work building brain implants that doctors can insert through blood vessels bloomberg.com/news/articles/…

Markets eye a potential tariff rollback while Evommune and @Aeromexico will make their Wall Street debuts on the NYSE. Elsewhere, @synchroninc announces it raised $200 Million in Series D funding. @Ash_TV has more in the market update.

➡️ Follow @NYSE for the daily Market Update

We’re excited to return as exhibitors at #ALSNexus2025, hosted by @alsassociation, an event where leaders across research, care, and advocacy come together to drive progress for the #ALS community.

Meet us at Booth #102.

More info: lnkd.in/esBiXEwe

During @theCUBE + @NYSE Wired: Medtech Unplugged Series, @dvellante spoke to @KurtHaggstrom about @synchroninc’s Brain Computer Interface (BCI) & how it’s less invasive, & more scalable & durable than Neuralink.

💡 More insights:
thecube.net/events/nyse/me…

@furrier @bjbaumann2014

Synchron combines brain implant with @Apple's BCI protocol to enable control of consumer electronic devices via neural signals.

longevity.technology/news/als-patie…

#longevity #neurotech #BCI #iPad #ALS

You can officially control an Apple device with your thoughts, as long as you have the Stentrode brain implant made by NYC-based Synchron.
pcmag.com/news/first-loo…

Synchron Debuts the First Thought-Controlled iPad Experience using Apple’s New BCI Human Interface Device Protocol tinyurl.com/3krbp25h

Apple's new thought control protocol has now been shown in use by Synchron, a medical company that has made a prototype for using iPads solely by thinking. By @WGallagher

appleinsider.com/articles/25/08…

In a remarkable first, Synchron has revealed the world’s first public demonstration of an iPad controlled purely by thought. thedebrief.org/synchron-unvei…

Synchron is the first company to connect its brain-computer interfaces to Apple products, and a video shows it in action for the first time—with one innovative new feature we didn't expect. pcmag.com/news/first-loo…